AnaCardio raised €62.5M in Series B funding.
- Amount
- $71M
- Stage
- Series B
- Announced
- 30 September 2026
- Leads
- Novo Holdings, Ljungström family office
- Other investors
- Helsinn, Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB, Innovestor Life Science
- Use of funds
- Fund Phase 2b clinical development of heart failure drug candidate AC01 toward Phase 3 readiness.
- Total raised
- $114M to date
- Checked
- Amount and date checked against the press source